All Stories

  1. Women’s perspectives on health service integration for multi-morbidity in pregnancy, childbirth, and postpartum in a high-burden setting
  2. Tracking children's immune responses reveals an antibody blueprint for fighting malaria
  3. Tfh2 and a subset of Tfh1 cells associate with antibody-mediated immunity to malaria
  4. Evaluation of whole blood CD64 for identifying infection in neonates receiving hospital care
  5. An abundant merozoite surface protein of Plasmodium falciparum modulates susceptibility to inhibitory antibodies
  6. Development of high affinity antibodies to Plasmodium falciparum merozoite and sporozoite antigens during infancy and adulthood
  7. Role of malaria exposure and off-target responses on RTS,S/AS02A vaccine immunogenicity and protection in Mozambican children
  8. Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections
  9. Plasmodium falciparum reticulocyte-binding homologues are targets of human inhibitory antibodies and play a role in immune evasion
  10. Antibody correlates of risk of clinical malaria in an area of low and unstable malaria transmission in western Kenya
  11. Functionally Distinct pTfh1 Subsets with Roles in Malaria-Specific Immunity
  12. Antimicrobials for Neonates: Practitioner Decisions and Diagnostic Certainty
  13. Detrimental infant and maternal outcomes of undiagnosed asymptomatic malaria in pregnancy
  14. IgM Is Prominent and Activates Complement in Acquired Transmission-Blocking Immunity Against Malaria
  15. Women's Perspectives on Health Service Integration Inform Strategies to Address Multi-Morbidity in Pregnancy, Childbirth and Postpartum in a High Burden Setting
  16. Induction of Fc-dependent functional antibodies against different variants of SARS-CoV-2 varies by vaccine type and prior infection
  17. Potent AMA1-specific human monoclonal antibody against Plasmodium vivax Pre-erythrocytic and Blood Stages
  18. Integrated Approaches for the Delivery of Maternal and Child Health Services with Childhood Immunization Programs in Low- and Middle-Income Countries: Systematic Review Update 2011–2020
  19. Heterogeneity of the human immune response to malaria infection and vaccination driven by latent cytomegalovirus infection
  20. Antibody mechanisms of protection against malaria in RTS,S-vaccinated children: a post-hoc serological analysis of phase 2 trial
  21. Mycoplasma genitalium in pregnancy, including specific co-infections, is associated with lower birthweight: A prospective cohort study
  22. A broadly cross-reactive i-body to AMA1 potently inhibits blood and liver stages of Plasmodium parasites
  23. IgM plays a prominent role in naturally acquired immunity against Plasmodium falciparum gametocytes
  24. Geospatial joint modeling of vector and parasite serology to microstratify malaria transmission
  25. Declining Antibody Affinity Over Time After Human Vaccination With a Plasmodium falciparum Merozoite Vaccine Candidate
  26. Heterogeneity of the human immune response to malaria infection and vaccination driven by latent cytomegalovirus infection
  27. Previous Malaria Exposures and Immune Dysregulation: Developing Strategies To Improve Malaria Vaccine Efficacy in Young Children
  28. A Diversity Covering (DiCo) Plasmodium vivax apical membrane antigen-1 vaccine adjuvanted with RFASE/RSL10 yields high levels of growth-inhibitory antibodies
  29. Potent AMA1-specific human monoclonal antibody against P. vivax Pre-erythrocytic and Blood Stages
  30. Potent AMA1-specific human monoclonal antibody against P. vivax Pre-erythrocytic and Blood Stages
  31. Clinical and immunological outcomes of HIV-exposed uninfected and HIV-unexposed uninfected children in the first 24 months of life in Western Kenya
  32. Complement detection on trophozoite stage Plasmodium falciparumparasites using flow cytometry or Western blot
  33. Plasmodium falciparum Growth or Invasion Inhibition Assays
  34. Antibody-dependent cell-mediated cytotoxicity (ADCC) assay with natural killer cells in malaria immunity
  35. Complement-fixation by antibodies to Plasmodium falciparum
  36. Isolation of viable Plasmodium falciparum merozoites
  37. Phagocytosis of antigen-coated beads or malaria parasites using neutrophils
  38. Quantifying antibody binding to Fcγ-receptors in malaria immunity
  39. Acquisition of complement fixing antibodies targeting Plasmodium falciparum merozoites in infants and their mothers in Uganda
  40. A step forward for Plasmodium falciparum malaria transmission-blocking vaccines
  41. Fc-dependent functional activity of ChAdOx1-S and CoronaVac vaccine-induced antibodies to the SARS-CoV-2 spike protein
  42. Associations between prenatal malaria exposure, maternal antibodies at birth, and malaria susceptibility during the first year of life in Burkina Faso
  43. Community perspectives and experiences of quality maternal and newborn care in East New Britain, Papua New Guinea
  44. The unfinished agenda of communicable diseases among children and adolescents before the COVID-19 pandemic, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
  45. Quantifying differences in iron deficiency-attributable anemia during pregnancy and postpartum
  46. Clinical and Immunological Outcomes of HIV-Exposed Uninfected and HIV-Unexposed Uninfected Children in the First 24 Months of Life in Western Kenya
  47. Antibody to Plasmodium falciparum Variant Surface Antigens, var Gene Transcription, and ABO Blood Group in Children With Severe or Uncomplicated Malaria
  48. Unfractionated heparin versus enoxaparin for venous thromboembolism prophylaxis in intensive care units: a propensity score adjusted analysis
  49. Defining species-specific and conserved interactions of apical membrane protein 1 during erythrocyte invasion in malaria to inform multi-species vaccines
  50. Low knowledge of newborn danger signs among pregnant women in Papua New Guinea and implications for health seeking behaviour in early infancy – findings from a longitudinal study
  51. Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
  52. The direct binding of Plasmodium vivax AMA1 to erythrocytes defines a RON2-independent invasion pathway
  53. Targeting malaria parasites with novel derivatives of azithromycin
  54. The RTS,S malaria vaccine: Current impact and foundation for the future
  55. Asia-Pacific ICEMR: Understanding Malaria Transmission to Accelerate Malaria Elimination in the Asia Pacific Region
  56. Impact of Environmental Modifications on the Ecology, Epidemiology, and Pathogenesis of Plasmodium falciparum and Plasmodium vivax Malaria in East Africa
  57. Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children
  58. Integrating de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes
  59. Assessment of IgG3 as a serological exposure marker for Plasmodium vivax in areas with moderate–high malaria transmission intensity
  60. Author Correction: Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique
  61. Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
  62. Antibody dynamics in children with first or repeat Plasmodium falciparum infections
  63. Age-dependent changes in circulating Tfh cells influence development of functional malaria antibodies in children
  64. Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia
  65. Quality newborn care in East New Britain, Papua New Guinea: measuring early newborn care practices and identifying opportunities for improvement
  66. Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S malaria vaccine in young children
  67. The Plasmodium falciparum parasitophorous vacuole protein P113 interacts with the parasite protein export machinery and maintains normal vacuole architecture
  68. Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study
  69. Quantification of the dynamics of antibody response to malaria to inform sero-surveillance in pregnant women
  70. Partnership-defined quality approach to companionship during labour and birth in East New Britain, Papua New Guinea: A mixed-methods study
  71. Adults with Plasmodium falciparum malaria have higher magnitude and quality of circulating T-follicular helper cells compared to children
  72. Age dependent changes in circulating Tfh cells influence the development of functional antibodies to malaria in children.
  73. Age dependent changes in circulating Tfh cells influence the development of functional antibodies to malaria in children
  74. Antibody Targets and Properties for Complement-Fixation Against the Circumsporozoite Protein in Malaria Immunity
  75. Multi-functional antibody profiling for malaria vaccine development and evaluation
  76. Recent clinical trials inform the future for malaria vaccines
  77. Reduced risk of placental parasitemia associated with complement fixation on Plasmodium falciparum by antibodies among pregnant women
  78. High Antibodies to VAR2CSA in Response to Malaria Infection Are Associated With Improved Birthweight in a Longitudinal Study of Pregnant Women
  79. Reduced risk of placental parasitaemia associated with complement fixation on Plasmodium falciparum by antibodies among pregnant women
  80. Community-based molecular and serological surveillance of subclinical malaria in Myanmar
  81. HIV infection and placental malaria reduce maternal transfer of multiple antimalarial antibodies in Mozambican women
  82. Mechanisms and targets of Fcγ-receptor mediated immunity to malaria sporozoites
  83. Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of Plasmodium falciparum Is Immunogenic and Induces Functional Antibody Responses in Mice
  84. Framework for Characterizing Longitudinal Antibody Response in Children After Plasmodium falciparum Infection
  85. Mycoplasma genitalium and Other Reproductive Tract Infections in Pregnant Women, Papua New Guinea, 2015–2017
  86. Complement Factors in COVID-19 Therapeutics and Vaccines
  87. Impact of a Rapid Decline in Malaria Transmission on Antimalarial IgG Subclasses and Avidity
  88. Risk factors and knowledge associated with high unintended pregnancy rates and low family planning use among pregnant women in Papua New Guinea
  89. RTS,S/AS01E malaria vaccine induces IgA responses against CSP and vaccine-unrelated antigens in African children in the phase 3 trial
  90. Novel virus-like particle vaccine encoding the circumsporozoite protein ofPlasmodium falciparumis immunogenic and induces functional antibody responses
  91. Th2-like T Follicular Helper Cells Promote Functional Antibody Production during Plasmodium falciparum Infection
  92. Sero-epidemiological evaluation of malaria transmission in The Gambia before and after mass drug administration
  93. Structure‐Activity Studies of Truncated Latrunculin Analogues with Antimalarial Activity
  94. Epitope masking may limit antibody boosting to malaria vaccines
  95. Improving the quality of maternal and newborn care in the Pacific region: A scoping review
  96. Retargeting azithromycin analogues to have dual-modality antimalarial activity
  97. Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia
  98. Evaluation of the effectiveness of topical repellent distributed by village health volunteer networks against Plasmodium spp. infection in Myanmar: A stepped-wedge cluster randomised trial
  99. Identifying and combating the impacts of COVID-19 on malaria
  100. Author Correction: Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique
  101. Antibody responses to a suite of novel serological markers for malaria surveillance demonstrate strong correlation with clinical and parasitological infection across seasons and transmission settings in The Gambia
  102. Impact of a rapid decline in malaria transmission on antimalarial IgG subclasses and avidity
  103. Iron Deficiency Is Associated With Reduced Levels of Plasmodium falciparum-specific Antibodies in African Children
  104. Antibody responses to the RTS,S/AS01E vaccine and Plasmodium falciparum antigens after a booster dose within the phase 3 trial in Mozambique
  105. High burden ofMycoplasma genitaliumand other reproductive tract infections among pregnant women in Papua New Guinea
  106. Th2-like T-follicular helper cells promote functional antibody production duringPlasmodium falciparuminfection
  107. Selection of Antibody Responses Associated With Plasmodium falciparum Infections in the Context of Malaria Elimination
  108. Sero-epidemiological evaluation of malaria transmission in The Gambia before and after mass drug administration
  109. Multifunctional Antibodies Are Induced by the RTS,S Malaria Vaccine and Associated With Protection in a Phase 1/2a Trial
  110. Strengthening routine immunization in Papua New Guinea: a cross-sectional provincial assessment of front-line services
  111. Multi-functional antibodies are induced by the RTS,S malaria vaccine and associated with protection in a phase I/IIa trial
  112. Strengthening routine immunization in Papua New Guinea: a cross-sectional provincial assessment of front-line services.
  113. Complement in malaria immunity and vaccines
  114. Novel particles for malaria vaccines
  115. IgM in human immunity to Plasmodium falciparum malaria
  116. Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced in Hansenula polymorpha
  117. Induction and Kinetics of Complement-Fixing Antibodies Against Plasmodium vivax Merozoite Surface Protein 3α and Relationship With Immunoglobulin G Subclasses and Immunoglobulin M
  118. RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study
  119. Iron deficiency, malaria, and low birth weight.
  120. Antibody Reactivity to Merozoite Antigens in Ghanaian Adults Correlates With Growth Inhibitory Activity Against Plasmodium falciparum in Culture
  121. Contribution of Functional Antimalarial Immunity to Measures of Parasite Clearance in Therapeutic Efficacy Studies of Artemisinin Derivatives
  122. Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity
  123. Display of malaria transmission-blocking antigens on chimeric duck hepatitis B virus-derived virus-like particles produced inHansenula polymorpha
  124. Differential Patterns of IgG Subclass Responses to Plasmodium falciparum Antigens in Relation to Malaria Protection and RTS,S Vaccination
  125. Dendritic Cell Responses and Function in Malaria
  126. Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein
  127. The salt between the beans: a qualitative study of the role of auxiliary midwives in a hard-to-reach area of Myanmar
  128. Understanding how the RTS,S malaria vaccine works
  129. Sulphadoxine-pyrimethamine plus azithromycin may improve birth outcomes through impacts on inflammation and placental angiogenesis independent of malarial infection
  130. Priority use cases for antibody-detecting assays of recent malaria exposure as tools to achieve and sustain malaria elimination
  131. Targeting malaria parasite invasion of red blood cells as an antimalarial strategy
  132. Targets of complement-fixing antibodies in protective immunity against malaria
  133. Different Life Cycle Stages of Plasmodium falciparum Induce Contrasting Responses in Dendritic Cells
  134. The impact of early life exposure to Plasmodium falciparum on the development of naturally acquired immunity to malaria in young Malawian children
  135. Antibody Responses to Antigenic Targets of Recent Exposure Are Associated With Low-Density Parasitemia in Controlled Human Plasmodium falciparum Infections
  136. Understanding transmission-blocking immunity compared to clinical immunity in malaria
  137. Challenges and strategies for developing efficacious and long-lasting malaria vaccines
  138. KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization
  139. Effectiveness of repellent delivered through village health volunteers on malaria incidence in villages in South-East Myanmar: a stepped-wedge cluster-randomised controlled trial protocol
  140. Loss of complement regulatory proteins on uninfected erythrocytes in vivax and falciparum malaria anemia
  141. Acquisition of Antibodies Against Endothelial Protein C Receptor–Binding Domains of Plasmodium falciparum Erythrocyte Membrane Protein 1 in Children with Severe Malaria
  142. Multiple morbidities in pregnancy: Time for research, innovation, and action
  143. Iron deficiency in pregnancy and poor birth outcomes
  144. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial
  145. Cellular dissection of malaria parasite invasion of human erythrocytes using viable Plasmodium knowlesi merozoites
  146. Factors influencing the induction of high affinity antibodies to Plasmodium falciparum merozoite antigens and how affinity changes over time
  147. Optimization of incubation conditions of Plasmodium falciparum antibody multiplex assays to measure IgG, IgG1–4, IgM and IgE using standard and customized reference pools for sero-epidemiological and vaccine studies
  148. The Complement System Contributes to Functional Antibody-Mediated Responses Induced by Immunization withPlasmodium falciparumMalaria Sporozoites
  149. Mechanism of immunity to malaria - blocking sporozoite infection
  150. Overcoming antigenic diversity of malaria vaccine candidates for better protection
  151. Proteome-wide mapping of immune features onto Plasmodium protein three-dimensional structures
  152. Combating low birth weight due to malaria infection in pregnancy.
  153. Effect of nutrient supplementation on the acquisition of humoral immunity to Plasmodium falciparum in young Malawian children
  154. Establishment of a yeast-based VLP platform for antigen presentation
  155. Antibodies generated by a vaccine against malaria in pregnancy
  156. The potential of task shifting selected maternal interventions to auxiliary midwives in Myanmar: a mixed-method study
  157. Immunity to severe malaria in children
  158. Sero-catalytic and Antibody Acquisition Models to Estimate Differing Malaria Transmission Intensities in Western Kenya
  159. Functional Conservation of the AMA1 Host-Cell Invasion Ligand Between P. falciparum and P. vivax: A Novel Platform to Accelerate Vaccine and Drug Development
  160. Impaired placental autophagy in placental malaria
  161. P. falciparum infection and maternofetal antibody transfer in malaria-endemic settings of varying transmission
  162. Identifying Immune Correlates of Protection Against Plasmodium falciparum Through a Novel Approach to Account for Heterogeneity in Malaria Exposure
  163. Understanding how immunity to malaria develops in children
  164. Identifying new drugs against malaria
  165. Acquisition, maintenance and adaptation of invasion inhibitory antibodies against Plasmodium falciparum invasion ligands involved in immune evasion
  166. The establishment of a WHO Reference Reagent for anti-malaria (Plasmodium falciparum) human serum
  167. Declining Transmission and Immunity to Malaria and Emerging Artemisinin Resistance in Thailand: A Longitudinal Study
  168. Dichotomous miR expression and immune responses following primary blood-stage malaria
  169. Impact of declining malaria transmission on human immunity
  170. The exported chaperone Hsp70-x supports virulence functions for Plasmodium falciparum blood stage parasites
  171. Host age and expression of genes involved in red blood cell invasion in Plasmodium falciparum field isolates
  172. Determinants of knowledge of critical danger signs, safe childbirth and immediate newborn care practices among auxiliary midwives: a cross sectional survey in Myanmar
  173. Prevention of postpartum haemorrhage by community-based auxiliary midwives in hard-to-reach areas of Myanmar: a qualitative inquiry into acceptability and feasibility of task shifting
  174. Antibody Responses to Plasmodium falciparum and Plasmodium vivax and Prospective Risk of Plasmodium spp. Infection Postpartum
  175. Host immunity to Plasmodium falciparum and the assessment of emerging artemisinin resistance in a multinational cohort
  176. The potential benefit of scaling up malaria prevention to reduce low birth weight in Africa
  177. Plasmodium vivax vaccine research – we’ve only just begun
  178. Inhibition of placental mTOR signaling provides a link between placental malaria and reduced birthweight
  179. Truncated Latrunculins as Actin Inhibitors Targeting Plasmodium falciparum Motility and Host Cell Invasion
  180. Evaluating Complement-Mediated Humoral Immunity to P. falciparum Blood Stages
  181. Differing rates of antibody acquisition in malaria: implications for immunity and surveillance
  182. Association between malaria immunity and pregnancy outcomes among Malawian pregnant women receiving nutrient supplementation
  183. Functional Antibodies and Protection against Blood-stage Malaria
  184. A malaria vaccine in children with HIV
  185. Structure–Activity Studies of β-Hairpin Peptide Inhibitors of the Plasmodium falciparum AMA1–RON2 Interaction
  186. A novel approach to identifying patterns of human invasion-inhibitory antibodies guides the design of malaria vaccines incorporating polymorphic antigens
  187. Specific antibodies to the PfRH5 invasion complex and protection from malaria
  188. Antibody responses to Plasmodium falciparum and Plasmodium vivax blood-stage and sporozoite antigens in the postpartum period
  189. The global threat of Zika virus to pregnancy: epidemiology, clinical perspectives, mechanisms, and impact
  190. Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite
  191. A single point in protein trafficking by Plasmodium falciparum determines the expression of major antigens on the surface of infected erythrocytes targeted by human antibodies
  192. Merozoite Antigens of Plasmodium falciparum Elicit Strain-Transcending Opsonizing Immunity
  193. Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2
  194. Maternal-foetal transfer of Plasmodium falciparum and Plasmodium vivax antibodies in a low transmission setting
  195. Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort
  196. Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria
  197. Immunity to malaria in an era of declining malaria transmission
  198. High resolution FTIR imaging provides automated discrimination and detection of single malaria parasite infected erythrocytes on glass
  199. Designing malaria vaccines to circumvent antigen variability
  200. Erratum to: CD14 hi CD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so
  201. Insights into the Immunological Properties of Intrinsically Disordered Malaria Proteins Using Proteome Scale Predictions
  202. Malaria and Age Variably but Critically Control Hepcidin Throughout Childhood in Kenya
  203. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases
  204. Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities
  205. Malaria eradication and elimination: views on how to translate a vision into reality
  206. Macrolides rapidly inhibit red blood cell invasion by the human malaria parasite, Plasmodium falciparum
  207. CD14hiCD16+ monocytes phagocytose antibody-opsonised Plasmodium falciparum infected erythrocytes more efficiently than other monocyte subsets, and require CD16 and complement to do so
  208. Differences in affinity of monoclonal and naturally acquired polyclonal antibodies against Plasmodium falciparum merozoite antigens
  209. Acquisition of Functional Antibodies That Block the Binding of Erythrocyte-Binding Antigen 175 and Protection AgainstPlasmodium falciparumMalaria in Children
  210. The impact of lipid-based nutrient supplementation on anti-malarial antibodies in pregnant women in a randomized controlled trial
  211. Maximizing antimalarial efficacy and the importance of dosing strategies
  212. Plasmodium vivax Malaria
  213. Risk factors for malaria and adverse birth outcomes in a prospective cohort of pregnant women resident in a high malaria transmission area of Papua New Guinea
  214. Conformational Dynamics and Antigenicity in the Disordered Malaria Antigen Merozoite Surface Protein 2
  215. Malaria and immunity during pregnancy and postpartum: a tale of two species
  216. Human Antibodies Fix Complement to Inhibit Plasmodium falciparum Invasion of Erythrocytes and Are Associated with Protection against Malaria
  217. PfRH5 as a candidate vaccine for Plasmodium falciparum malaria
  218. Acquisition of Antibodies against Plasmodium falciparum Merozoites and Malaria Immunity in Young Children and the Influence of Age, Force of Infection, and Magnitude of Response
  219. Research priorities for the development and implementation of serological tools for malaria surveillance
  220. Limited antigenic diversity of Plasmodium falciparumapical membrane antigen 1 supports the development of effective multi-allele vaccines
  221. Immunological markers of Plasmodium vivaxexposure and immunity: a systematic review and meta-analysis
  222. Use of Immunodampening To Overcome Diversity in the Malarial Vaccine Candidate Apical Membrane Antigen 1
  223. PTEX is an essential nexus for protein export in malaria parasites
  224. Opsonic phagocytosis of Plasmodium falciparummerozoites: mechanism in human immunity and a correlate of protection against malaria
  225. Decreasing Malaria Prevalence and Its Potential Consequences for Immunity in Pregnant Women
  226. Surface antigens of Plasmodium falciparum-infected erythrocytes as immune targets and malaria vaccine candidates
  227. A critical evaluation of pyrrolo[2,3-d]pyrimidine-4-amines as Plasmodium falciparum apical membrane antigen 1 (AMA1) inhibitors
  228. Subclass responses and their half-lives for antibodies against EBA175 and PfRh2 in naturally acquired immunity against Plasmodium falciparum malaria
  229. Overcoming Antigenic Diversity by Enhancing the Immunogenicity of Conserved Epitopes on the Malaria Vaccine Candidate Apical Membrane Antigen-1
  230. Sequential Processing of Merozoite Surface Proteins during and after Erythrocyte Invasion by Plasmodium falciparum
  231. Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines
  232. Antibodies to Polymorphic Invasion-Inhibitory and Non-Inhibitory Epitopes of Plasmodium falciparum Apical Membrane Antigen 1 in Human Malaria
  233. Erythrocyte-Binding Antigens ofPlasmodium falciparumAre Targets of Human Inhibitory Antibodies and Function To Evade Naturally Acquired Immunity
  234. Identification and Prioritization of Merozoite Antigens as Targets of Protective Human Immunity to Plasmodium falciparum Malaria for Vaccine and Biomarker Development
  235. Acquired Antibodies to Merozoite Antigens in Children from Uganda with Uncomplicated or Severe Plasmodium falciparum Malaria
  236. Reply to Eisenhut
  237. PfEMP1 as a target of human immunity and a vaccine candidate against malaria
  238. Does Malaria Affect Placental Development? Evidence from In Vitro Models
  239. Defining the Timing of Action of Antimalarial Drugs against Plasmodium falciparum
  240. New approaches to studying Plasmodium falciparum merozoite invasion and insights into invasion biology
  241. Platelet Factor 4 and Duffy Antigen Required for Platelet Killing of Plasmodium falciparum
  242. Defining the Antigenic Diversity of Plasmodium falciparum Apical Membrane Antigen 1 and the Requirements for a Multi-Allele Vaccine against Malaria
  243. Antibody Boosting and Longevity Following Tetanus Immunization During Pregnancy
  244. The Plasmodium falciparum Erythrocyte Invasion Ligand Pfrh4 as a Target of Functional and Protective Human Antibodies against Malaria
  245. Antigenic Characterization of an Intrinsically Unstructured Protein, Plasmodium falciparum Merozoite Surface Protein 2
  246. New Insights into Acquisition, Boosting, and Longevity of Immunity to Malaria in Pregnant Women
  247. Targets of antibodies against Plasmodium falciparum–infected erythrocytes in malaria immunity
  248. Malaria Parasite Signal Peptide Peptidase is an ER‐Resident Protease Required for Growth but not for Invasion
  249. Plasmodium vivax Adherence to Placental Glycosaminoglycans
  250. Perspectives: The missing pieces
  251. Intermittent Preventive Treatment for Malaria in Papua New Guinean Infants Exposed to Plasmodium falciparum and P. vivax: A Randomized Controlled Trial
  252. High Affinity Antibodies to Plasmodium falciparum Merozoite Antigens Are Associated with Protection from Malaria
  253. Antibody to P. falciparum in Pregnancy Varies with Intermittent Preventive Treatment Regime and Bed Net Use
  254. Quantifying the Importance of MSP1-19 as a Target of Growth-Inhibitory and Protective Antibodies against Plasmodium falciparum in Humans
  255. A Phase 1 Trial of MSP2-C1, a Blood-Stage Malaria Vaccine Containing 2 Isoforms of MSP2 Formulated with Montanide® ISA 720
  256. Discovery of GAMA, a Plasmodium falciparum Merozoite Micronemal Protein, as a Novel Blood-Stage Vaccine Candidate Antigen
  257. IgG against Plasmodium falciparum variant surface antigens and growth inhibitory antibodies in Mozambican children receiving intermittent preventive treatment with sulfadoxine-pyrimethamine
  258. Antibodies to a Full-Length VAR2CSA Immunogen Are Broadly Strain-Transcendent but Do Not Cross-Inhibit Different Placental-Type Parasite Isolates
  259. Intermittent Preventive Treatment to Reduce the Burden of Malaria in Children: New Evidence on Integration and Delivery
  260. Placental Malaria-Associated Inflammation Disturbs the Insulin-like Growth Factor Axis of Fetal Growth Regulation
  261. Super-Resolution Dissection of Coordinated Events during Malaria Parasite Invasion of the Human Erythrocyte
  262. Reticulocyte and Erythrocyte Binding-Like Proteins Function Cooperatively in Invasion of Human Erythrocytes by Malaria Parasites
  263. Evidence That the Erythrocyte Invasion Ligand PfRh2 is a Target of Protective Immunity against Plasmodium falciparum Malaria
  264. Stepwise dissection of Plasmodium falciparum merozoite invasion of the human erythrocyte
  265. Association between Naturally Acquired Antibodies to Erythrocyte‐Binding Antigens ofPlasmodium falciparumand Protection from Malaria and High‐Density Parasitemia
  266. Minimal Association of Common Red Blood Cell Polymorphisms with Plasmodium falciparum Infection and Uncomplicated Malaria in Papua New Guinean School Children
  267. Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand
  268. Isolation of viable Plasmodium falciparum merozoites to define erythrocyte invasion events and advance vaccine and drug development
  269. Interactions with heparin-like molecules during erythrocyte invasion by Plasmodium falciparum merozoites
  270. Using an Improved Phagocytosis Assay to Evaluate the Effect of HIV on Specific Antibodies to Pregnancy-Associated Malaria
  271. Antibodies to Chondroitin Sulfate A–Binding Infected Erythrocytes: Dynamics and Protection during Pregnancy in Women Receiving Intermittent Preventive Treatment
  272. Immunization with VAR2CSA-DBL5 Recombinant Protein Elicits Broadly Cross-Reactive Antibodies to Placental Plasmodium falciparum-Infected Erythrocytes
  273. Evaluation of the Antigenic Diversity of Placenta-Binding Plasmodium falciparum Variants and the Antibody Repertoire among Pregnant Women
  274. The Relationship between Anti-merozoite Antibodies and Incidence of Plasmodium falciparum Malaria: A Systematic Review and Meta-analysis
  275. Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assays
  276. Strain-Specific Duffy Binding Protein Antibodies Correlate with Protection against Infection with Homologous Compared to Heterologous Plasmodium vivax Strains in Papua New Guinean Children
  277. The future for blood‐stage vaccines against malaria
  278. Cellular Tumor Necrosis Factor, Gamma Interferon, and Interleukin-6 Responses as Correlates of Immunity and Risk of Clinical Plasmodium falciparum Malaria in Children from Papua New Guinea
  279. Sir2 Paralogues Cooperate to Regulate Virulence Genes and Antigenic Variation in Plasmodium falciparum
  280. Antibodies to Reticulocyte Binding Protein-Like Homologue 4 Inhibit Invasion of Plasmodium falciparum into Human Erythrocytes
  281. Reticulocyte-binding protein homologue 5 – An essential adhesin involved in invasion of human erythrocytes by Plasmodium falciparum
  282. Immunoglobulin G Subclass-Specific Responses against Plasmodium falciparum Merozoite Antigens Are Associated with Control of Parasitemia and Protection from Symptomatic Illness
  283. Analysis of structure and function of the giant protein Pf332 in Plasmodium falciparum
  284. Recent insights into humoral and cellular immune responses against malaria
  285. Acquisition of Growth-Inhibitory Antibodies against Blood-Stage Plasmodium falciparum
  286. Antibody-Mediated Growth Inhibition of Plasmodium falciparum: Relationship to Age and Protection from Parasitemia in Kenyan Children and Adults
  287. Exported Proteins Required for Virulence and Rigidity of Plasmodium falciparum-Infected Human Erythrocytes
  288. Estimating the Burden of Global Mortality in Children Aged <5 Years by Pathogen‐Specific Causes
  289. Characteristics of Plasmodium falciparum-Infected-Erythrocyte Adhesion to Chondroitin Sulfate
  290. Polymorphic and Conserved Targets of Antibodies againstPlasmodium falciparumduring Pregnancy
  291. Truncation of Plasmodium berghei merozoite surface protein 8 does not affect in vivo blood-stage development
  292. Variation in use of erythrocyte invasion pathways by Plasmodium falciparum mediates evasion of human inhibitory antibodies
  293. Characterization of VAR2CSA-deficient Plasmodium falciparum-infected erythrocytes selected for adhesion to the BeWo placental cell line
  294. Towards a Vaccine against Plasmodium vivax Malaria
  295. Structural Basis for Binding of Plasmodium falciparum Erythrocyte Membrane Protein 1 to Chondroitin Sulfate and Placental Tissue and the Influence of Protein Polymorphisms on Binding Specificity
  296. Serum Lipoproteins Promote Efficient Presentation of the Malaria Virulence Protein PfEMP1 at the Erythrocyte Surface
  297. Antibodies among Men and Children to Placental-Binding Plasmodium falciparum-Infected Erythrocytes that Express var2csa
  298. THE RISK OF MALARIAL INFECTIONS AND DISEASE IN PAPUA NEW GUINEAN CHILDREN
  299. Skeleton-binding protein 1 functions at the parasitophorous vacuole membrane to traffic PfEMP1 to the Plasmodium falciparum–infected erythrocyte surface
  300. Development and Optimization of High-Throughput Methods To Measure Plasmodium falciparum-Specific Growth Inhibitory Antibodies
  301. Antigenic Differences and Conservation among PlacentalPlasmodium falciparum–Infected Erythrocytes and Acquisition of Variant‐Specific and Cross‐Reactive Antibodies
  302. A var gene promoter controls allelic exclusion of virulence genes in Plasmodium falciparum malaria
  303. Promising Functional Readouts of Immunity in a Blood-Stage Malaria Vaccine Trial
  304. Targets of Protective Antibodies to Malaria during Pregnancy
  305. Placental Malaria Induces Variant-Specific Antibodies of the Cytophilic Subtypes Immunoglobulin G1 (IgG1) and IgG3 That Correlate with Adhesion Inhibitory Activity
  306. Cross-Reactive Surface Epitopes on Chondroitin Sulfate A-Adherent Plasmodium falciparum-Infected Erythrocytes Are Associated with Transcription of var2csa
  307. Broad analysis reveals a consistent pattern of var gene transcription in Plasmodium falciparum repeatedly selected for a defined adhesion phenotype
  308. The Immunology and Pathogenesis of Malaria During Pregnancy
  309. Clinical features and pathogenesis of severe malaria
  310. Malaria in pregnancy and the endemicity spectrum: what can we learn?
  311. Impairment of humoral immunity to Plasmodium falciparum malaria in pregnancy by HIV infection
  312. Phenotypes of Plasmodium falciparum from the Peripheral Blood of Pregnant Women
  313. Antibodies to Variant Surface Antigens ofPlasmodium falciparum–Infected Erythrocytes and Adhesion Inhibitory Antibodies Are Associated with Placental Malaria and Have Overlapping and Distinct Targets
  314. Plasmodium falciparum–Infected Erythrocytes Demonstrate Dual Specificity for Adhesion to Hyaluronic Acid and Chondroitin Sulfate A and Have Distinct Adhesive Properties
  315. An alternative agglutination assay to measure antibodies to variant surfaceantigens of Plasmodium falciparum-infected erythrocytes
  316. Selective Accumulation of Mature Asexual Stages of Plasmodium falciparum-Infected Erythrocytes in the Placenta
  317. Evaluating specific adhesion of Plasmodium falciparum-infected erythrocytes to immobilised hyaluronic acid with comparison to binding of mammalian cells
  318. The Structural Motif in Chondroitin Sulfate for Adhesion ofPlasmodium falciparum-infected Erythrocytes Comprises Disaccharide Units of 4-O-Sulfated and Non-sulfated N-Acetylgalactosamine Linked to Glucuronic Acid
  319. Expanding the paradigms of placental malaria
  320. Pathogenesis of Plasmodium falciparum malaria: the roles of parasite adhesion and antigenic variation
  321. Parasite adhesion and immune evasion in placental malaria
  322. Sticky rings: challenging the cytoadherence dogma
  323. New agents to combat malaria
  324. Inhibition of Adhesion of Plasmodium falciparum-Infected Erythrocytes by Structurally Defined Hyaluronic Acid Dodecasaccharides
  325. Identification of Glycosaminoglycan Binding Domains in Plasmodium falciparum Erythrocyte Membrane Protein 1 of a Chondroitin Sulfate A-Adherent Parasite
  326. Plasmodium falciparum Rosette Formation Is Uncommon in Isolates from Pregnant Women
  327. Adhesion of Plasmodium falciparum-infected erythrocytes to hyaluronic acid in placental malaria
  328. The placenta in malaria: mechanisms of infection, disease and foetal morbidity
  329. The placenta in malaria: mechanisms of infection, disease and foetal morbidity
  330. Plasmodium falciparumIsolates from Infected Pregnant Women and Children Are Associated with Distinct Adhesive and Antigenic Properties
  331. The adhesion ofPlasmodium falciparum-infected erythrocytes to chondroitin sulfate A is mediated byP. falciparumerythrocyte membrane protein 1
  332. Inhibition of Binding of Malaria-Infected Erythrocytes by a Tetradecasaccharide Fraction from Chondroitin Sulfate A
  333. Age and damage induced changes in amyloid protein precursor immunohistochemistry in the rat brain
  334. Differential distribution of amyloid protein precursor immunoreactivity in the rat brain studied by using five different antibodies
  335. Synthesis and transacylating reactivity of β-cyclodextrin ethylenediamines